文献速递哮喘

重症哮喘生物制剂:选哪个、何时用、为何用?

Biologics for severe asthma-Which, when and why?
PubMed 文献 · Respirology · 2023-05-24

生物制剂革新了重症哮喘管理,但并非万能,临床需求仍未满足。

要点

  • 重症哮喘占哮喘患者的5%-10%,疾病负担重、医疗资源利用高。
  • 生物制剂主要改变2型免疫介导重症哮喘的管理预期,可探索改变疾病轨迹与诱导缓解。
  • 生物制剂并非所有重症哮喘的万能方案,仍存在显著未满足的临床需求。

核心结论

  • 生物制剂革新了重症哮喘的管理,尤其对2型免疫介导者,可探索改变疾病轨迹和诱导缓解。
  • 生物制剂并非所有重症哮喘患者的万能方案,尽管成功,仍有大量未满足的临床需求。

研究设计与样本

  • 综述:回顾哮喘发病机制、哮喘异质性表型分析、目前已获批和未来的生物制剂。

主要发现

  • 哮喘管理目标是控制疾病,即减少症状和急性加重,并减少糖皮质激素相关疾病负担。

关键数值与推荐

  • 综述汇总了如何选择初始生物制剂、评估治疗反应、判断缓解及切换生物制剂的策略。

临床怎么用

  • 临床可依据哮喘表型(尤其2型免疫特征)选择初始生物制剂,并系统评估反应、缓解与切换。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma is a common chronic inflammatory condition of the airways that affects about 350 million people globally. In 5%-10% of individuals, it is severe, with considerable morbidity and high health care utilization. The goal of asthma management is disease control by reducing symptoms and exacerbations and reducing corticosteroid-related morbidity. The era of biologics has revolutionized the management of severe asthma. Biologics have changed our expectations for severe asthma, especially in those people with type-2 mediated immunity. We can now explore the potential for changing disease trajectory and inducing remission. However, biologics are not a panacea for all severe asthma sufferers and despite their success there remains substantial unmet clinical need. We review the pathogenesis of asthma, phenotyping the heterogeneity of asthma, currently licensed and future biologic agents, how to choose the initial biologic, assessing the response, remission and switching of biologic therapies.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Shah PA, Brightling C. Biologics for severe asthma-Which, when and why? Respirology. 2023. PMID: 37222237. doi:10.1111/resp.14520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。